Effect of "lipid metabolism" related genotypes on the treatment response by PUFA add-on therapy for bipolar disorder(2)
Not Applicable
- Conditions
- Bipolar Disorder
- Registration Number
- JPRN-UMIN000033503
- Lead Sponsor
- Fujita Health University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 53
Inclusion Criteria
Not provided
Exclusion Criteria
-Bipolar disorder (rapid cycling) diagnosed by DSM-V -patients who are taking EPA/DHA -Allergy for EPA/DHA -metabolic syndrome at the enrollment -side effect by EPA/DHA -high risk of hemorrhage -patients who received more than 3 types of antipsychotics -patients who received more than 3 types of antidepressants (exclude antidepressants which use only as hypnotics)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method "depressive" phase (at enrollment)" Outcome: improve rate of MADRS (at 12 week) "remission" (at enrollment) Outcome: recurrent rate (YMRS/MADRS >=13) Maximum 52 weeks follow up (first visit, 2w, 4w, every 4weeks thereafter)
- Secondary Outcome Measures
Name Time Method "depressive" phase (at enrollment)" Response (50% reduction of MADRS) and non-response rates Remission (YMRS/MADRS<=12) and non-remission rates CGI change at the final weeks RNA/Protein/lipid concentration (Cholesterol/HDL/LDL/TG, omega3 and omega 6 PUFAs)